Nora Therapeutics Is Hoping To Teach An Old Dog New Tricks In Fertility
This article was originally published in The Pink Sheet Daily
Executive Summary
Having raised an $18 million Series B, Nora is continuing a Phase II trial of lead G-CSF candidate NT100 in IVF failure. But the biotech also has begun enrolling a second Phase II study in women with unexplained recurrent miscarriage.
You may also be interested in...
Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier
To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.
Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier
To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.